Partial
Partially Aligned
Patient Risk:
Low
Summary
The AI response makes several non-supported opioid-statin interaction claims and includes multiple statements not reflected in the Lipitor label. It correctly notes dose-related myopathy risk and certain population considerations (elderly and hepatic impairment) that are present in the label, but overall the output contains contradicted, unsupported, and off-label statements. Therefore, partial alignment with the prescribing information.
Category Scores
Accurate Statements
Atorvastatin is metabolized by cytochrome P450 3A4; opioids are metabolized by various CYP enzymes.
12.3, 7.1
The risk of statin-associated myopathy/rhabdomyolysis is dose-related and may be increased with concomitant therapy.
5.1
Monitor for unexplained muscle pain, dark urine, or fatigue.
5.1
Elderly patients or those with liver impairment require caution or dose considerations.
8.5, 8.6
Unsupported Statements
Lipitor has no major documented interactions with opioids like oxycodone, hydrocodone, morphine, or fentanyl.
Labeling describes interactions with strong CYP3A4 inhibitors, not opioid-specific interactions; no opioid class warning.
They do not significantly compete or inhibit each other at typical doses.
Label indicates potential interaction via CYP3A4 inhibitors increasing atorvastatin exposure.
Rare cases report increased statin side effects when combining with fentanyl or methadone due to CYP3A4 overlap.
Not documented in Lipitor label.
Less than 1% of users are affected per clinical reports.
No incidence rate provided in label for opioid co-use.
No large-scale studies confirm opioids directly worsen Lipitor's common issues like headache, nausea, or diarrhea.
No opioid-specific causality claim in label.
Opioids like fentanyl strongly inhibit CYP3A4, potentially raising atorvastatin blood levels and amplifying muscle-related risks.
Label does not state opioids inhibit CYP3A4.
Weaker CYP3A4 opioids (e.g., codeine, tramadol) pose minimal concern.
No opioid-by-opioid stratified data in label.
Adjust doses or switch statins (e.g., to pravastatin) if high-risk opioids are involved.
Not opioid-specific in label; not stated.
No opioid-specific warnings appear on Lipitor's label.
Label has warnings about myopathy with interacting drugs, not opioid-specific warnings.
These align with statin side effects alone, not clear causation.
Label does not attribute causation to opioids.
Always check opioid-statin pairs with Liverpool Drug Interactions checker.
Tool name not in label; off-label.
User forums and FDA adverse event reports note occasional muscle aches or fatigue in combined use.
Postmarketing reports exist; labeling indicates myopathy; causality not established.
Adjust doses or switch statins due to opioid involvement.
Not described in label.
Contradictions
Low
AI Statement
They do not significantly compete or inhibit each other at typical doses.
Label Reference
7.1, 5.1
Important Omissions
The label's Drug Interactions section emphasizes increased atorvastatin exposure with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors, ritonavir-containing regimens) and provides specific dose adjustment guidance (e.g., lower atorvastatin doses when combined with these agents).
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Misstatements about opioid-statin interactions are not supported by label; main safety signals come from myopathy/rhabdomyolysis risk with interacting agents, which are acknowledged by the AI analysis.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Opioid-statin interaction claims are not supported by the Lipitor label; some statements align with dose-related myopathy risk and population considerations, but numerous claims are unsupported or contradicted by the label.
Suggested Improvement
Restrict assertions to label-supported interactions (e.g., with strong CYP3A4 inhibitors) and avoid opioid-specific interaction claims; remove incidence figures and tool recommendations not present in the label; cite relevant sections (7, 5.1, 8.5, 8.6, 12.3).